Outlook Therapeutics Appoints Laura Cantrell As Vice President Of Corporate Strategy And Business Development

Outlook Therapeutics, Inc., a biopharmaceutical company focused on advancing the standard of care for bevacizumab in the treatment of retinal diseases, announced the appointment of Laura Cantrell as Vice President of Corporate Strategy and Business Development.

In her new role, Ms. Cantrell will lead Outlook Therapeutics’ business development and corporate strategy initiatives, including strategic partnerships, licensing opportunities, and broader corporate development efforts aimed at supporting the company’s long-term growth objectives.

“We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.”

Ms. Cantrell brings more than two decades of experience in global corporate strategy, business development, and portfolio leadership across the biotechnology and pharmaceutical sectors. She is a seasoned biotech executive with deep expertise in business development execution, commercial strategy, and global portfolio expansion.

Throughout her career, Ms. Cantrell has held senior leadership roles at prominent biotechnology companies, including Medivation (acquired by Pfizer), BeiGene, Sobi, Axovant Sciences, and Genentech/Roche. She has led numerous high-impact licensing, acquisition, and partnership transactions and was a core member of the team supporting Medivation’s $14 billion acquisition by Pfizer, as well as the commercial assessment underpinning Pfizer’s acquisition of TALZENNA.

“I am excited to join Outlook Therapeutics and to work alongside the leadership team at such an important moment for the Company,” said Laura Cantrell, newly appointed Vice President of Corporate Strategy and Business Development. “I look forward to leveraging my experience in business development, global partnerships and portfolio strategy to help advance the company’s programs, explore strategic opportunities and support Outlook’s next phase of growth.”

Ms. Cantrell has extensive experience driving global commercialization strategies and lifecycle management for biologics and oncology assets, including bevacizumab, and has led asset teams responsible for product launches and regulatory approvals across North America, Europe, and other international markets. She holds an MBA from Emory University and a Bachelor of Science in Biology from the University of Michigan.